FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103122153> ?p ?o ?g. }

• W2103122153 endingPage "1743" @default.
• W2103122153 startingPage "1737" @default.
• W2103122153 abstract "Chronic graft-versus-host disease (GVHD) induces significant morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Corticosteroids are standard initial therapy, despite limited efficacy and long-term toxicity. Based on our experience using bortezomib as effective acute GVHD prophylaxis, we hypothesized that proteasome-inhibition would complement the immunomodulatory effects of corticosteroids to improve outcomes in chronic GVHD (cGVHD). We undertook a single-arm phase II trial of bortezomib plus prednisone for initial therapy of cGVHD. Bortezomib was administered at 1.3 mg/m(2) i.v. on days 1, 8, 15, and 22 of each 35-day cycle for 3 cycles (15 weeks). Prednisone was dosed at .5 to 1 mg/kg/day, with a suggested taper after cycle 1. All 22 enrolled participants were evaluable for toxicity; 20 were evaluable for response. Bortezomib plus prednisone therapy was well tolerated, with 1 occurrence of grade 3 sensory peripheral neuropathy possibly related to bortezomib. The overall response rate at week 15 in evaluable participants was 80%, including 2 (10%) complete and 14 (70%) partial responses. The organ-specific complete response rate was 73% for skin, 53% for liver, 75% for gastrointestinal tract, and 33% for joint, muscle, or fascia involvement. The median prednisone dose decreased from 50 mg/day to 20 mg/day at week 15 (P < .001). The combination of bortezomib and prednisone for initial treatment of cGVHD is feasible and well tolerated. We observed a high response rate to combined bortezomib and prednisone therapy; however, in this single-arm study, we could not directly measure the impact of bortezomib. Proteasome inhibition may offer benefit in the treatment of cGVHD and should be further evaluated." @default.
• W2103122153 created "2016-06-24" @default.
• W2103122153 creator A5001407163 @default.
• W2103122153 creator A5008718116 @default.
• W2103122153 creator A5021084465 @default.
• W2103122153 creator A5029278364 @default.
• W2103122153 creator A5029390145 @default.
• W2103122153 creator A5030788778 @default.
• W2103122153 creator A5031812464 @default.
• W2103122153 creator A5045479163 @default.
• W2103122153 creator A5053410437 @default.
• W2103122153 creator A5054037976 @default.
• W2103122153 creator A5058268746 @default.
• W2103122153 creator A5068050082 @default.
• W2103122153 creator A5074589634 @default.
• W2103122153 creator A5079056163 @default.
• W2103122153 date "2014-11-01" @default.
• W2103122153 modified "2023-10-02" @default.
• W2103122153 title "A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease" @default.
• W2103122153 cites W1483732515 @default.
• W2103122153 cites W1512261733 @default.
• W2103122153 cites W1967356384 @default.
• W2103122153 cites W1976913166 @default.
• W2103122153 cites W1977166918 @default.
• W2103122153 cites W1977298956 @default.
• W2103122153 cites W1991519628 @default.
• W2103122153 cites W1991948976 @default.
• W2103122153 cites W1995326684 @default.
• W2103122153 cites W2005604237 @default.
• W2103122153 cites W2005758735 @default.
• W2103122153 cites W2022664029 @default.
• W2103122153 cites W2041355950 @default.
• W2103122153 cites W2049808194 @default.
• W2103122153 cites W2054710330 @default.
• W2103122153 cites W2062576298 @default.
• W2103122153 cites W2068547289 @default.
• W2103122153 cites W2078346968 @default.
• W2103122153 cites W2086030126 @default.
• W2103122153 cites W2087613277 @default.
• W2103122153 cites W2096491215 @default.
• W2103122153 cites W2100088787 @default.
• W2103122153 cites W2102755845 @default.
• W2103122153 cites W2103185055 @default.
• W2103122153 cites W2106495043 @default.
• W2103122153 cites W2106877484 @default.
• W2103122153 cites W2109346271 @default.
• W2103122153 cites W2110395869 @default.
• W2103122153 cites W2112193890 @default.
• W2103122153 cites W2114277323 @default.
• W2103122153 cites W2122277484 @default.
• W2103122153 cites W2122684890 @default.
• W2103122153 cites W2130884024 @default.
• W2103122153 cites W2133590829 @default.
• W2103122153 cites W2139184776 @default.
• W2103122153 cites W2143436585 @default.
• W2103122153 cites W2144789671 @default.
• W2103122153 cites W2157583708 @default.
• W2103122153 cites W2164199065 @default.
• W2103122153 cites W2164945798 @default.
• W2103122153 cites W2167504424 @default.
• W2103122153 cites W2171005667 @default.
• W2103122153 cites W2618073389 @default.
• W2103122153 doi "https://doi.org/10.1016/j.bbmt.2014.06.040" @default.
• W2103122153 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4465759" @default.
• W2103122153 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25017765" @default.
• W2103122153 hasPublicationYear "2014" @default.
• W2103122153 type Work @default.
• W2103122153 sameAs 2103122153 @default.
• W2103122153 citedByCount "44" @default.
• W2103122153 countsByYear W21031221532014 @default.
• W2103122153 countsByYear W21031221532015 @default.
• W2103122153 countsByYear W21031221532016 @default.
• W2103122153 countsByYear W21031221532017 @default.
• W2103122153 countsByYear W21031221532018 @default.
• W2103122153 countsByYear W21031221532019 @default.
• W2103122153 countsByYear W21031221532020 @default.
• W2103122153 countsByYear W21031221532021 @default.
• W2103122153 countsByYear W21031221532022 @default.
• W2103122153 countsByYear W21031221532023 @default.
• W2103122153 crossrefType "journal-article" @default.
• W2103122153 hasAuthorship W2103122153A5001407163 @default.
• W2103122153 hasAuthorship W2103122153A5008718116 @default.
• W2103122153 hasAuthorship W2103122153A5021084465 @default.
• W2103122153 hasAuthorship W2103122153A5029278364 @default.
• W2103122153 hasAuthorship W2103122153A5029390145 @default.
• W2103122153 hasAuthorship W2103122153A5030788778 @default.
• W2103122153 hasAuthorship W2103122153A5031812464 @default.
• W2103122153 hasAuthorship W2103122153A5045479163 @default.
• W2103122153 hasAuthorship W2103122153A5053410437 @default.
• W2103122153 hasAuthorship W2103122153A5054037976 @default.
• W2103122153 hasAuthorship W2103122153A5058268746 @default.
• W2103122153 hasAuthorship W2103122153A5068050082 @default.
• W2103122153 hasAuthorship W2103122153A5074589634 @default.
• W2103122153 hasAuthorship W2103122153A5079056163 @default.
• W2103122153 hasBestOaLocation W21031221531 @default.
• W2103122153 hasConcept C126322002 @default.
• W2103122153 hasConcept C141071460 @default.
• W2103122153 hasConcept C143998085 @default.

• next